Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access programEditta Baldini, Diana Giannarelli, Alice Lunghi et al.|Lung Cancer|2019Cited by 42
Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second waveAlice Indini, Livio Blasi, Fabrizio Artioli et al.|European Journal of Cancer|2021Cited by 22
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with GefitinibRiziero Esposito Abate, Nicola Normanno, Raffaella Pasquale et al.|Cancers|2019Cited by 10
Treatment of acute myeloid leukemia and myelodysplastic syndrome by low dose arabinosyl cytosine.Michele Baccarani, Lorenzo Lodi, Gianpiero Fasola et al.|PubMed|1985Cited by 1
Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programmeE.H. Baldini, Diana Giannarelli, Alessandro Lunghi et al.|Annals of Oncology|2018Cited by 1